0201 Clinical Trial 2017-0224IBRUTINIB Clinical Trial...
Paolo Strati, M.D., Department of Lymphoma - Myeloma, Division of Cancer Medicine
View lymphoma clinical trials and multiple myeloma clinical trials being conducted by MD Anderson Cancer Center, a top ranked cancer center.
Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.